50 completed, 8 terminated, 6 unknown, 2 recruiting. 22 Phase 4, 15 Phase 3, 14 Phase 1, 9 Not applicable, 7 Phase 2.
Follow Rivastigmine: new trials by email Literature Review of Rivastigmine trials Research Report on Rivastigmine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Rivastigmine for Antimuscarinic Delirium Rivastigmine, Placebo - Anticholinergic Toxicity | Phase 2 | Recruiting | Washington University School of Medicine | 42 | 2026-06-01 | 2026-06-04 |
| Rivastigmine as an Antidote for Clozapine-induced Central Nervous System Depression and Delirium Rivastigmine - Anticholinergic Delirium, Clozapine Poisoning | Phase 4 | Completed | Alexandria University | 100 | 2025-12-08 | 2026-09-21 |
| Intravenous Infusion of Umbilical Cord Blood as an Adjunctive Treatment for Alzheimer's Disease Intravenous infusion of mononuclear cells from umbilical cord blood, Conventional medical treatment：donepezil, rivastigmine or galantamine - Alzheimer Disease (AD) | Early Phase 1 | Recruiting | Anhui Provincial Hospital | 30 | 2025-07-31 | 2025-10-06 |
| Rivastigmine to Prevent Recurrence of Antimuscarinic Delirium Rivastigmine, Placebo - Anticholinergic Toxicity | Phase 2 | Suspended | Washington University School of Medicine | 42 | 2024-11-04 | 2026-06-04 |
| Comparison of Therapeutic Strategies With Cholinesterase Inhibitors (SOS TRIAL) cholinesterase inhibitors (CI) (donepezil, galantamine or rivastigmine) - Alzheimer Disease, Cholinesterase Inhibitors | Phase 4 | Not yet recruiting | University Hospital, Bordeaux | 1205 | 2024-06-01 | 2023-10-06 |
| Safety and Efficacy of AR1005 in Patients with Lewy Body Disease AR1005, Placebo, Rivastigmine 3 mg - Lewy Body Dementia | Phase 2 | Unknown | Yonsei University | 60 | 2024-01-01 | 2024-10-02 |
| Rivastigmine Transdermal Patches Bioequivalence and Adhesion Assessment Rivastigmine TDS 9,5 mg/24 h, Exelon® 9.5 mg/24 h - Bioequivalence Study in Healthy Subjects | Phase 1 | Completed | Zodiac Produtos Farmaceuticos S.A. | 68 | 2023-05-12 | 2026-03-11 |
| Rivastigmine Bioequivalence Trial With Multiple Application of Transdermal Patches (13.3mg/24h) RID-TDS 13.3 mg/24 h, Exelon® 13.3 mg/24 h - Healthy | Phase 1 | Completed | Luye Pharma Group Ltd. | 48 | 2023-05-02 | 2023-10-19 |
| Rivastigmine Bioequivalence Trial With Multiple Applications of Transdermal Patches (9.5 mg/24 h) Rivastigmine twice-weekly 9,5 mg/24 h, Exelon® 9.5 mg/24 h - Bioequivalence | Phase 1 | Completed | SocraTec R&D GmbH | 38 | 2023-04-17 | 2024-02-02 |
| Telerehabilitation Alzheimer's Disease Feasibility (TADF) BrightGo cognitive training, Standard of Care medication for early Alzheimer's Disease - Alzheimer Disease, Healthy Aging | Not applicable | Unknown | Bright Cloud International Corp | 14 | 2022-02-16 | 2022-05-02 |
| Deep Brain Stimulation for Alzheimer's Disease Deep brain stimulation, Best medical treatment for Alzheimer's disease - Alzheimer Disease, Dementia, Alzheimer Type | Not applicable | Unknown | Buddhist Tzu Chi General Hospital | 30 | 2020-04-06 | 2020-07-17 |
| Nutraceuticals and Drug Treatment in Frail Older Adults Nutraceuticals - Frailty | Unknown | University of Campania Luigi Vanvitelli | 485 | 2020-04-01 | 2022-05-10 | |
| Rivastigmine Patch Compared to Melatonin Patch in Prevention of Postoperative Delirium Rivastigmine Transdermal System [Exelon], Melatonin - Delirium | Phase 1 / Phase 2 | Completed | Ain Shams University | 180 | 2019-11-18 | 2020-07-09 |
| Effect of Heat on Rivastigmine TDS Products Rivastigmine (RLD) transdermal patch, Rivastigmine (generic) transdermal patch - Bioavailability | Early Phase 1 | Completed | University of Maryland, Baltimore | 7 | 2019-10-04 | 2022-04-04 |
| Noradrenaline, Acetylcholine and Dynamic Learning in Healthy Humans Reboxetine, Rivastigmine, Placebo oral tablet - Healthy | Not applicable | Completed | University of Oxford | 107 | 2019-06-01 | 2020-06-16 |
| A Phase IV Study to Evaluate Safety, Tolerability and Effectiveness of Rivastigmine Patch 15cm2 in Patients With Severe Dementia of the Alzheimer's Type. Rivastigmine - Alzheimer's Disease | Phase 4 | Completed | Novartis Pharmaceuticals | 100 | 2018-12-31 | 2024-05-31 |
| Rivastigmine Bioequivalence Trial With Multiple Application of Transdermal Patches (9.5mg/24h) RID-TDS 9.5 mg/24 h, Exelon® 9.5 mg/24 h - Bioequivalence | Phase 1 | Completed | SocraTec R&D GmbH | 58 | 2018-08-22 | 2019-09-19 |
| Rivastigmine BA Trial With Multiple Application of Transdermal Patches, Adaptation and Tapering Phase RIV-TDS 13.3 mg/24 h, Exelon® 13.3 mg/24 hours transdermal patch - Bioequivalence | Phase 1 | Completed | SocraTec R&D GmbH | 36 | 2018-05-16 | 2018-08-21 |
| Efficacy of RIVAstigmine on Motor, Cognitive and Behavioural Impairment in Progressive Supranuclear Palsy Rivastigmine, Placebo - Progressive Supranuclear Palsy (PSP) | Phase 3 | Completed | Assistance Publique Hopitaux De Marseille | 106 | 2016-07-26 | 2023-07-20 |
| NextStep:Study to Evaluate Safety,Efficacy & Tolerability of Rivastigmine Patch in Mild to Moderate Alzheimer's Patients. Rivastigmine Patch - Mild to Moderate Alzheimer's Disease | Phase 4 | Completed | Novartis Pharmaceuticals | 118 | 2016-05-09 | 2019-09-12 |
Showing 20 of 69. Sign in to see all of them.
Alzheimer Disease (28) · Dementia (12) · Cognitive Dysfunction (7) · Cognition Disorders (3) · Delirium (3) · Parkinson Disease (3) · Stroke (3) · Substance-Related Disorders (3) · Brain Injuries, Traumatic (2) · Butyrylcholinesterase deficiency (2) · Dementia, Vascular (2) · Down Syndrome (2) · Lewy Body Disease (2) · Memory Disorders (2) · Supranuclear Palsy, Progressive (2)
Novartis (12) · Novartis Pharmaceuticals (8) · SocraTec R&D GmbH (3) · Baylor College of Medicine (2) · Dr. Reddy's Laboratories Limited (2) · Sunnybrook Health Sciences Centre (2) · UMC Utrecht (2) · University Hospital Muenster (2) · Washington University School of Medicine (2) · Ain Shams University (1) · Alexandria University (1) · Amsterdam UMC, location VUmc (1) · Anhui Provincial Hospital (1) · Assistance Publique Hopitaux De Marseille (1) · Bright Cloud International Corp (1)
United States (22) · Germany (12) · France (9) · Canada (6) · Spain (6) · Italy (5) · Netherlands (4) · United Kingdom (4) · China (3) · South Korea (3) · Taiwan (3) · Australia (2) · Austria (2) · Brazil (2) · Egypt (2)
Caterina Breitenstein, PhD (2) · Kevin Baumgartner, MD (2) · Richard Larouche, M.D (2) · Stefan Knecht, MD (2) · Arjen JC Slooter, MD. PhD. (1) · Audra L Stinchcomb, PhD (1) · Beth Safirstein, M.D. (1) · Byoung Seok Ye, MD, PhD (1) · Daniela Berg, Doctor (1) · David Devos, MD, PhD (1) · David R. Hassmann, D.O. (1) · Elisabeth Foncke, Dr. (1)
PMID 10662747, PMID 11904109, PMID 11927799, PMID 12119802, PMID 12832331, PMID 15066944, PMID 15710782, PMID 15738343, PMID 16880771, PMID 17509485, PMID 17515447, PMID 17515448, PMID 18674411, PMID 20837887, PMID 21056464, PMID 21274364, PMID 22311903, PMID 23782591, PMID 23982674, PMID 24218528, PMID 24938502, PMID 25523430, PMID 25755685, PMID 26482056, PMID 27271310, PMID 28295141, PMID 28550255, PMID 35287171, PMID 35498050, PMID 35696054, PMID 39498781, PMID 39727053, PMID 9727818
2018 (2), 2008 (1), 2016 (1), 2023 (1), P50DA018185 (1), P50NS062684 (1), R01DA023624 (1), R01DA023964 (1), R43AG065035 (1)